Sequential changes of serum ferritin levels and their clinical significance in lamivudine-treated patients with chronic viral hepatitis B

World Journal of Gastroenterology

Volumn 10, Issue 7, 2004, Pages 972-976

  Liu, Zheng Wen ^a   Han, Qun Ying ^a   Zhang, Ni ^a   Kang, Wen ^a  

^a XI'AN JIAOTONG UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; FERRITIN; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIBODY; HEPATITIS B(E) ANTIGEN; HERBACEOUS AGENT; IMMUNOSUPPRESSIVE AGENT; LAMIVUDINE; VIRUS DNA;

ADOLESCENT; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIVIRAL ACTIVITY; ARTICLE; BLOOD CHEMISTRY; CLINICAL ARTICLE; CLINICAL OBSERVATION; CONTROLLED STUDY; DNA DETERMINATION; DOSE RESPONSE; FEMALE; FERRITIN BLOOD LEVEL; FLUORESCENCE ANALYSIS; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; MALE; NONHUMAN; PATIENT MONITORING; POLYMERASE CHAIN REACTION; PROSPECTIVE STUDY; QUANTITATIVE ANALYSIS; RADIOIMMUNOASSAY; SEQUENTIAL ANALYSIS; SEROCONVERSION; SERODIAGNOSIS; VIRUS PATHOGENESIS;

EID: 1842686790     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v10.i7.972     Document Type: Article

References (44)

1. Margolis HS, Alter MJ, Hadler SC. Hepatitis B: Evolving epidemiology and implications for control. Semin Liver Dis 1991; 11: 84-92
2. Sherlock S. Viruses and hepatocellular carcinoma. Gut 1994; 35: 828-832
3. Yip D, Findlay M, Boyer M, Tattersall MH. Hepatocellular carcinoma in central Sydney: A 10-year review of patients seen in a medical oncology department. World J Gastroenterol 1999; 5: 483-487
4. Tang ZY. Hepatocellular carcinoma-cause, treatment and metastasis. World J Gastroenterol 2001; 7: 445-454
5. Liaw YF, Tai DI, Chu CM, Chen TJ. The development of cirrhosis in patients with chronic type B hepatitis: A prospective study. Hepatology 1988; 8: 493-496
6. Hoofnagle JH, di Bisceglie AM. The treatment of chronic viral hepatitis. N Engl J Med 1997; 336: 347-356
7. Carreno V, Bartolome J, Castillo I. Long-term effect of interferon therapy in chronic hepatitis B. J Hepatol 1994; 20: 431-435
8. Bayraktar Y, Koseoglu T, Temizer A, Kayhan B, Van Thiel DH, Uzunalimoglu B. Relationship between the serum alanine aminotransferase level at the end of interferon treatment and histologic changes in wild-type and precore mutant hepatitis B virus infections. J Viral Hepat 1996; 3: 137-142
9. Tine F, Liberati A, Craxi A, Almasio P, Pagliaro L. Interferon treatment in patients with chronic hepatitis B: A meta-analysis of the published literature. J Hepatol 1993; 8: 154-162
10. Di Bisceglie AM. Long-term outcome of interferon-alpha therapy for chronic hepatitis B. J Hepatol 1995; 22(1 Suppl): 65-67
11. Lau DT, Everhart J, Kleiner DE, Park Y, Vergalla J, Schmid P, Hoofnagle JH. Long-term follow-up of patients with chronic hepatitis B treated with interferon alfa. Gastroenterology 1997; 113: 1660-1667
12. Han HL, Lang ZW. Changes in serum and histology of patients with chronic hepatitis B after interferon alpha-2b treatment. World J Gastroenterol 2003; 9: 117-121
13. Dienstag JL, Perrillo RP, Schiff ER, Bartholomew M, Vicary C, Rubin M. A preliminary trial of lamivudine for chronic hepatitis B infection. N Engl J Med 1995; 333: 1657-1661
14. Schalm SW, de Man RA, Heijtink RA, Niesters HG. New nucleoside analogues for chronic hepatitis B. J Hepatol 1995; 22(1 Suppl): 52-56
15. Lai CL, Chien RN, Leung NW, Chang TF, Guan R, Tai DI, Ng KY, Wu PC, Dent JC, Barber J, Stephenson SL, Gray DF. A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. N Engl J Med 1998; 339: 61-68
16. Lau DT, Khokhar MF, Doo E, Ghany MG, Herion D, Park Y, Kleiner DE, Schmid P, Condreay LD, Gauthier J, Kuhns MC, Liang TJ, Hoofnagle JH. Long-term therapy of chronic hepatitis B with lamivudine. Hepatology 2000; 32(4 Pt 1): 828-834
17. Song BC, Suh DJ, Lee HC, Chung YH, Lee YS. Hepatitis B e antigen seroconversion after lamivudine therapy is not durable in patients with chrondc hepatitis B in Korea. Hepatology 2000; 32(4 Pt 1): 803-806
18. Yang SS, Hsu CT, Hu JT, Lai YC, Wu CH. Lamivudine does not increase the efficacy of interferon in the treatment of mutant type chronic viral hepatitis B. World J Gastroenterol 2002; 8: 868-871
19. Dienstag JL, Schiff ER, Wright TL, Perrillo RP, Hann HW, Goodman Z, Crowther L, Condreay LD, Woessner M, Rubin M, Brown NA. Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med 1999; 341: 1256-1263
20. Liaw YF, Leung NW, Chang TT, Guan R, Tai DI, Ng KY, Chien RN, Dent J, Roman L, Edmundson S, Lai CL. Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. Gastroenterology 2000; 119: 172-180
21. Brook MG, Karayiannis P, Thomas HC. Which patients with chronic hepatitis B virus infection will respond to alpha-interferon therapy? A statistical analysis of predictive factors. Hepatology 1989; 10: 761-763
22. Chien RN, Liaw YF, Atkins M. Pretherapy alanine transaminase level as a determinant for hepatitis B e antigen seroconversion during lamivudine therapy in patients with chronic hepatitis B. Asian Hepatitis Lamivudine Trial Group. Hepatology 1999; 30: 770-774
23. Schalm SW, Heathcote J, Cianciara J, Farrell G, Sherman M, Willems B, Dhillon A, Moorat A, Barber J, Gray DF. Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: A randomised trial. Gut 2000; 46:562-568
24. Lustbader ED, Hann HW, Blumberg BS. Serum ferritin as a predictor of host response to hepatitis B virus infection. Science 1983; 220: 423-425
25. Cohen C, Berson SD, Shulman G, Budgeon LR. Liver iron stores and hepatitis B antigen status. Cancer 1985; 56: 2201-2204
26. Hengeveld P, Zuyderhoudt FM, Jobsis AC, van Gool J. Some aspects of iron metabolism during acute viral hepatitis. Hepatogastroenterology 1982; 29: 138-141
27. Zhou XD, DeTolla L, Custer RP, London WT. Iron, ferritin, hepatitis B surface and core antigens in the livers of Chinese patients with hepatocellular carcinoma. Cancer 1987; 59: 1430-1437
28. Hann HW, Kim CY, London WT, Blumberg BS. Increased serum ferritin in chronic liver disease: A risk factor for primary hepatocellular carcinoma. Int J Cancer 1989; 43: 376-379
29. Di Bisceglie AM, Axiotis CA, Hoofnagle JH, Bacon BR. Measurements of iron status in patients with chronic hepatitis. Gastroenterology 1992; 102: 2108-2113
30. Cao Z, Bai Y, Yang X, Liu J, Li B, Li F. Study of iron metabolism abnormality in the hepatocyte damage of hepatitis B. Zhonghua Ganzangbing Zazhi 2001; 9: 37-39
31. Jurczyk K, Wawrzynowicz-Syczewska M, Boron-Kaczmarska A, Sych Z. Serum iron parameters in patients with alcoholic and chronic cirrhosis and hepatitis. Med Sci Monit 2001; 7: 962-965
32. You J, Zhuang L, Tang BZ, Yang WB, Ding SY, Li W, Wu RX, Zhang HL, Zhang YM, Yan SM, Zhang L. A randomized controlled clinical trial on the treatment of Thymosin-a1 versus interferon-alpha in patients with hepatitis B. World J Gastroenterol 2001; 7: 411-414
33. Zhuang L, You J, Tang BZ, Ding SY, Yan KH, Peng D, Zhang YM, Zhang L. Preliminary results of Thymosin-a1 versus interferon-alpha treatment in patients with HBeAg negative and serum HBV DNA positive chronic hepatitis B. World J Gastroenterol 2001; 7: 407-410
34. Terrault NA. Combined interferon and lamivudine therapy: Is this the treatment of choice for patients with chronic hepatitis B virus infection? Hepatology 2000; 32: 675-677
35. Farrell G. Hepatitis B e antigen seroconversion:eFfects of lamivudine alone or in combination with interferon alpha. J Med Virol 2000; 61: 374-379
36. Jaboli MF, Fabbri C, Liva S, Azzaroli F, Nigro G, Giovanelli S, Ferrara F, Miracolo A, Marchetto S, Montagnani M, Colecchia A, Festi D, Reggiani LB, Roda E, Mazzella G. Long-term alpha interferon and lamivudine combination therapy in non-responder patients with anti-HBe-positive chronic hepatitis B: Results of an open, controlled trial. World J Gastroenterol 2003; 9: 1491-1495
37. Liu P, Hu YY, Liu C, Zhu DY, Xue HM, Xu ZQ, Xu LM, Liu CH, Gu HT, Zhang ZQ. Clinical observation of salvianolic acid B in treatment of liver fibrosis in chronic hepatitis B. World J Gastroenterol 2002; 8: 679-685
38. Chen XS, Wang GJ, Cai X, Yu HY, Hu YP. Inhibition of hepatitis B virus by oxymatrine in vivo. World J Gastroenterol 2001; 7: 49-52
39. Weng HL, Cai WM, Liu RH. Animal experiment and clinical study of effect of gamma-interferon on hepatic fibrosis. World J Gastroenterol 2001; 7: 42-48
40. Wu JM, Lin JS, Xie N, Liang KH. Inhibition of hepatitis B virus by a novel L-nucleoside, β-L-D4A and related analogues. World J Gastroenterol 2003; 9: 1840-1843
41. 1 and traditional medicine preparation. World J Gastroenterol 1999; 5: 267-269
42. Bayraktar Y, Saglam F, Temizer A, Uzunalimodlu B, van Thiel DH. The effect of interferon and desferrioxamine on serum ferritin and hepatic iron concentrations in chronic hepatitis B. Hepatogastroenterology 1998; 45: 2322-2327
43. Sumida Y, Nakashima T, Yoh T, Kakisaka Y, Nakajima Y, Ishikawa H, Mitsuyoshi H, Okanoue T, Nakamura H, Yodoi J. Serum thioredoxin elucidates the significance of serum ferritin as a marker of oxidative stress in chronic liver diseases. Liver 2001; 21: 295-299
44. Chrobot A, Chrobot AM, Szaflarska-Szczepanik A. Assessment of iron metabolism in children with chronic hepatitis B - prognostic factor in interferon alpha therapy. Med Sci Monit 2002; 8: CR269-273